Plasmon on track to being ‘sales-led’ firm; to go ahead with £10m share placement

Plasmon plc, providers of professional archival solutions, reiterated its plan, subject to shareholder approval, to issue 100 million new ordinary shares through a placing to raise £10m.

The company also issued a trading update yesterday. It said that despite softness in US IT markets which has had some impact on its legacy and hardware product sales, the overall archive storage market is forecast to grow from $9bn in 2007 to $23bn by 2010.

The Cambridge HQed firm said its Archive Appliance sales growth remains in excess of 50% in constant currency terms after the first nine months of the current year, compared to the comparable period last year, and is the focus of growth plans.

Plasmon says it has best-in-class solutions for customers in the archive market, particularly those seeking to move essential, but rarely-accessed, data archives from expensive hard disk (RAID) servers to a lower cost, more permanent storage infrastructure tier.

In order to fully capture this market opportunity, new CEO Steven Murphy (pictured), is extending and accelerating the growth strategy. He is building a customer-facing marketing, sales and service channel to win major account business and support Resellers.

The Board said it believes this will enable the Group to deliver significant future sales growth and complete its transformation from a "technology-led" to a "sales-led" business.

Recruitment of new senior sales executives (predominantly US-based) has been underway since late 2007, and most have now been identified and are ready to join the business.

Nine out of 14 of these senior executives have signed offer letters and have had successful careers with industry storage leaders.

Primarily as a result of this investment in a faster growth strategy, Plasmon has deferred its cash break-even target to second half of financial year 2009.

The Group said its growth strategy builds on two successes achieved in 2007. First, the signing of 18 new reseller channel partners and second, a major programme of operational restructuring, which has so far reduced the overhead cost base by 20%.

Plasom expects to reduce headcount by 25% when outsourcing of hardware manufacturing is concluded in June.

Contribution margin on sales is now approaching management's target of 60%, it said.

The company’s shares are quoted at 11.5p pre-market opening, valuing it at almost £14m, down from £21m late last year.

20th February 2008

Previous articles
MMI Group's focus on drug development causes losses to widen
Next generation medical diagnostics closer after SmartBead, FingerPrint merger
Ubisense, a 'company to watch in 2006'
Another Fen biotech is swallowed as Acambis Board gives the nod to Sanofi Pastuer’s £276m takeover offer
Briefs: Xaar sees short term sales, not profits, hit from China’s earthquake; MMI to focus on its DNA oncology technology
Cambridge Enterprise 04/05 income up: consultancy 'more focussed'
Mobile payment processor Bango's flurry of deals warms market
Amino Technologies sees solid revenue growth but profit hit by weaker dollar
News briefs: ARM expands in India; Amino signs Caribbean deal
Silicon Fen icon Gerald Avison moves upstairs at TTP Group
Subscribe

 

Corporate profiles

 • BioProgress


Richard Trevillion
Chief Executive Officer


BioProgress plc develops and commercialises patents covering water soluble and biodegradable films, and process machinery, and has recently set up a new pharmaceutical division - Dexo BioPharm - that applies its technologies to products, develops new products and markets the enhanced products directly. BioProgress

[BioProgress's profile]


Top20 Index




Currently: 71.78


Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.